Midza (Lacosamide)

Lacosamide, the active ingredient in Midza, is a Sodium channel blocker presented as a tablet for oral use. It is used to treat partial‑onset seizures as part of epilepsy management in adults and children when appropriate.

GNH USA supplies Midza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide acts on neuronal sodium channels to control seizure activity in epilepsy.

- Partial‑onset seizures: adjunctive treatment to reduce seizure frequency. - Epilepsy (adjunctive therapy): helps control seizures when other medications are insufficient. - Focal seizures (monotherapy): can be prescribed as initial therapy for seizure control.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Fatigue: feeling unusually tired or weak. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of depressive thoughts. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Respiratory depression: especially when combined with other CNS depressants.

Before prescribing or dispensing lacosamide, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: avoid use in patients with known PR‑interval prolongation without cardiology input. - Pregnancy: risk category unknown; discuss potential benefits and risks with the prescriber. - Concomitant CNS depressants: monitor for additive sedation or respiratory effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lacosamide can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce lacosamide exposure. - Class I antiarrhythmics (e.g., quinidine): additive effects on cardiac conduction. - Carbamazepine: may lower lacosamide efficacy.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: monitor seizure control and plasma concentrations. - Alcohol: may enhance central nervous system depression. - Tramadol: increased risk of seizures when combined.